Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study

Tropical Medicine and International Health

Volumn 20, Issue 11, 2015, Pages 1431-1437

  Zhang, Xiulei ^a   Yin, Jia ^b   Li, Haitao ^a   Li, Shuguang ^a   Walley, John ^c   Zou, Guanyang ^c   Zhang, Zhitong ^c   Wei, Xiaolin ^b  

^a SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

China; diagnosis delay; multidrug resistant tuberculosis; second line drugs; treatment delay

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

DISEASE TREATMENT; DRUG RESISTANCE; HEALTH CARE; HEALTH EDUCATION; HEALTH SERVICES; MANAGEMENT PRACTICE; PUBLIC HEALTH; SPATIOTEMPORAL ANALYSIS; TRAINING; TUBERCULOSIS;

ARTICLE; CROSS-SECTIONAL STUDY; DELAYED DIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT ATTITUDE; RELAPSE; RETREATMENT; SPUTUM SMEAR; STRUCTURED QUESTIONNAIRE; THERAPY DELAY; TIME TO TREATMENT;

CHINA; SHANDONG;

EID: 84973480900     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12566     Document Type: Article

References (26)

1. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization: Geneva, Switzerland, 2008b.
2. World Health Organization. Guidelines for Treatment of Tuberculosis (4th edn), World Health Organization: Geneva, 2009.
3. Albert H, Bwanga F, Mukkada S, et al. Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis 2010: 10: 41.
4. Shen X, DeRiemer K, Yuan ZA, et al. Drug-resistant tuberculosis in Shanghai, China, 2000–2006: prevalence, trends and risk factors. Int J Tuberculosis Lung Dis 2009: 13: 253–259.
5. Zhao M, Li X, Xu P, et al. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS ONE 2009: 4: e4370.
6. Velasquez GE, Yagui M, Cegielski JP, et al. Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005–2008. Emerg Infect Dis 2011: 17: 432–440.
7. World Health Organization. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB):2010 Global Report on Surveillance and Response. World Health Organization: Geneva, 2010.
8. China's Ministry of Health. Report of National TB Drug Resistance Survey (2007–2008). People's Health Press: Beijing, 2010.
9. China's Ministry of Health. Guidelines for Implementing the National Tuberculosis Control Program in China (2008). Peking Union Medical College Press: Beijing, 2009.
10. World Health Organization. Anti-Tuberculosis Drug Resistance in the World. World Health Organization: Geneva, 2008a.
11. Wang Y. Multi-Drug Resistant Tuberculosis Control and Management Guideline. Military Medical Science Press: Beijing, 2012.
12. World Health Organization. Global Tuberculosis Control Report. World Health Organization: Geneva, 2012.
13. Narasimooloo R, Ross A. Delay in commencing treatment for MDR TB at a specialised TB treatment centre in KwaZulu-Natal. S Afr Med J 2012: 102: 360–362.
14. Bamford C, Taljaard J. Potential for nosocomial transmission of multidrug-resistant tuberculosis (MDR TB) in a South African hospital. S Afr Med J 2010: 100: 438–441.
15. Gler MT, Guilatco RS, Guray CV. Screening outcomes form patients with suspected multidrug-resistant tuberculosis: lessons learned in the Philippines. Int J Tuberc Lung Dis 2012: 16: 1326–1330.
16. Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010: 14: 131–140.
17. Yagui M, Perales MT, Asencios L, et al. Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis 2006: 10: 838–843.
18. Chen Q, Zheng J, Wu N. Analysis on the correlated factors of delay in tuberculosis diagnosis and treatment in Fujian province. Chin J Anti-Tuberculosis Assoc 2005: 27: 374–379.
19. Liang L, Wu Q, Gao L, et al. Factors contributing to the high prevalence of muntidrug-resistant tuberculosis: a study from China. Thorax 2012: 67: 632–638.
20. Meng Q, Li R, Cheng G, Blas E. Provision and financial burden of TB services in a financially decentralized system: a case study from Shandong, China. Int J Health Plan Manage 2004: 19: s45–s62.
21. Wei X, Zou G, Walley J, et al. China tuberculosis policy at crucial crossroads: comparing the practice of different hospital and tuberculosis control collaboration models using survey data. PLoS ONE 2014: 9: e99150.
22. Wei X, Zou G, Yin J, Walley J, Sun Q. Comparing patient care seeking pathways in three models of hospital and TB programme collaboration in China. BMC Infect Dis 2013: 13: 93.
23. Hu Y, Hoffner S, Wu L, Zhao Q, Jiang W, Xu B. Prevalence and genetic characterization of second-line drug- resistant and extensively drug-resistant Mycobacterium tuberculosis in rural China. Antimicrob Agents Chemother 2013: 57: 3857–3863.
24. Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med 2009: 150: 766–775.
25. Espinal M, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001: 5: 887–893.
26. Wei X-L, Yin J, Zou G-Y, et al. Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China. Int J Tuberc Lung Dis 2015: 19: 413–419.